New research takes p*** out of incontinence

February 20, 2020

Millions of people might eventually be spared the embarrassment and extreme isolation caused by wetting themselves, thanks to new research.

One in every five people has a lower urinary tract disorder called overactive bladder which, for some, means not being able to hold in urine, needing to go to the toilet often, or waking in the night to empty their bladder.

Some wear sanitary towels or disposable underwear, while others worry that even with absorbent underwear, they'll smell of urine, so they choose instead to stay at home.

Now, scientists at the University of Portsmouth have identified chemicals in urine that are specific to overactive bladder. The next step is to develop a gadget similar to a pregnancy test, to see if these chemical markers are present. Such a device is 12-24 months from clinical trials, but the early signs are encouraging.

Dr John Young and Dr Sepinoud Firouzmand, both in the School of Pharmacy and Biomedical Sciences at Portsmouth, published their research in Nature's Scientific Reports.

Dr Young, who led the research, said: "The first step has been to identify chemicals in urine that are specific to overactive bladder. The next step is to develop a gadget for use in GPs, pharmacies and nursing or care homes which is simple to use, accurate and doesn't need to be sent to a laboratory for processing.

"If successful, it would save millions of patients from painful procedures and long waits for a diagnosis."

It would also save healthcare providers, including the National Health Service (NHS), millions of pounds.

Dr Young said: "This is the first step in transforming the lives of millions of people who suffer in silence, too embarrassed to go out or even to speak about their condition.

"It is not too strong to say this could be a game changer."

If clinical trials bear out the development, it would allow treatment for the condition to begin much earlier.

Urinary disorders affect 20 percent of the population as a whole. By the age of 50, one in three people will have a urinary disorder.

Diagnosing an overactive bladder - when a patient needs to urinate very often, and sometimes wets their pants - is, at best, a cumbersome process. Clinicians need to first rule out a wide range of possible diseases and conditions with the same symptoms, including some cancers, Type 2 diabetes, cystitis, and a urinary tract infection. One of these tests is invasive and painful and costs £1,000 per person. The treatments for each possible disease varies greatly. Some of the tests aren't accurate at giving a clear result, prolonging clinicians' search for a diagnosis.

The conditions can be so complex to diagnose, that patients' health has often worsened by the time the results are finally in.

The dipstick test Dr Young and colleagues are proposing would cost about £10 and take a few minutes to give an accurate result.

Treatment could start immediately, long before the sometimes debilitating symptoms have forced a patient to wear sanitary products, or to stop going out altogether to avoid wetting themselves in public.

"It'd be as simple as a pregnancy test," Dr Young said. "Effective treatment is early treatment. When left untreated, the bladder can change. Additional nerves, blood vessels and cells grow, leaving it smaller than before. "It isn't good enough that so many millions of people feel forced to isolate themselves in their homes, avoiding all social interaction, with a condition which if caught early, has treatments which can help."
-end-
**Paper available - please note embargo 10:00 GMT Thursday, February 20, 2020

University of Portsmouth

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.